Bozó Aliz

1.

Kovács, F., Jakab, Á., Balla, N., Tóth, Z., Balázsi, D., Forgács, L., Harmath, A., Bozó, A., Ragyák, Á., Majoros, L., Kovács, R. L.: A comprehensive analysis of the effect of quorum-sensing molecule 3-oxo-C12-homoserine lactone on Candida auris and Candida albicans.
Biofilm. 9, 1-12, (article identifier: 100259), 2025.

doi DEA WoS Scopus

Journal metrics:

Q2 Cell Biology (2023)

Q1 Applied Microbiology and Biotechnology (2023)

Q2 Molecular Biology (2023)

Q2 Microbiology (2023)

2.

Pinna, A., Donadu, M. G., Dore, S., Serra, R., Sacchi, M., Boscia, G., Bozó, A., Kovács, R. L.: In Vitro Activity of a New Ophthalmic Spray Containing Biosecur® Citrus Extract (Oftasecur®) Against Candida auris and Candida albicans and Preformed Biofilm on Contact Lenses.
Vision. 9 (1), 1-10, (article identifier: 12), 2025.

doi DEA

Journal metrics:

Q4 Cell Biology (2023)

Q3 Cognitive Neuroscience (2023)

Q2 Ophthalmology (2023)

Q2 Optometry (2023)

Q3 Sensory Systems (2023)

3.

Balla, N., Kovács, F., Tóth, Z., Harmath, A., Bozó, A., Majoros, L., Kovács, R. L., Jakab, Á.: Isolate Specific Transcriptome Changes Exerted by Isavuconazole Treatment in Candida auris.
Mycopathologia. 190 (1), 1-11, (article identifier: 5), 2025.

doi DEA WoS Scopus

Journal metrics:

Q1 Agronomy and Crop Science (2023)

Q2 Applied Microbiology and Biotechnology (2023)

Q2 Microbiology (2023)

Q1 Plant Science (2023)

D1 Veterinary (miscellaneous) (2023)

4.

Kovács, R. L., Árokszállási, T., Bozó, A., Jakab, Á., Rab-Bábel, K. S., Héja, M., Kovács, K. B., Balázs, B., Vitális, E., Majoros, L., Tóth, Z.: Bacteraemia Associated with Bilophila wadsworthia: a Rare Case Presentation from Hungary.
Pathogens. 13 (9), 1-7, (article identifier: 749), 2024.

doi DEA

Journal metrics:

Q2 Infectious Diseases (2023)

Q2 Immunology and Allergy (2023)

Q2 Immunology and Microbiology (miscellaneous) (2023)

Q2 Microbiology (medical) (2023)

Q2 Molecular Biology (2023)

5.

Kovács, F., Balla, N., Bozó, A., Harmath, A., Jakab, Á., Tóth, Z., Nagy, F., Majoros, L., Kovács, R. L.: Epidemiology, clinical characteristics, outcome and biofilm forming properties in candidaemia: a single-centre retrospective 4-year analysis from Hungary.
Mycoses. 67 (4), 1-12, (article identifier: 13727), 2024.

doi DEA WoS Scopus

Journal metrics:

Q1 Dermatology (2023)

Q2 Infectious Diseases (2023)

Q1 Medicine (miscellaneous) (2023)

6.

Tóth, Z., Bozó, A., Kovács, R. L., Balogh, B., Balázs, B., Forgács, L., Kelentey, B., Majoros, L.: The In Vitro Activity of Fluconazole, Amphotericin B and Echinocandins Against Cyberlindnera fabianii Planktonic Cells and Biofilms.
Mycopathologia. 188 (1-2), 111-118, 2023.

doi DEA WoS Scopus

Journal metrics:

Q1 Agronomy and Crop Science

Q2 Applied Microbiology and Biotechnology

Q2 Microbiology

Q1 Plant Science

D1 Veterinary (miscellaneous)

7.

Balla, N., Jakab, Á., Kovács, F., Ragyák, Á., Tóth, Z., Balázsi, D., Forgács, L., Bozó, A., Al Refai, F., Borman, A. M., Majoros, L., Kovács, R. L.: Total transcriptome analysis of Candida auris planktonic cells exposed to tyrosol.
AMB Express. 13 (1), 1-10, (article identifier: 81), 2023.

doi DEA WoS Scopus

Journal metrics:

Q2 Applied Microbiology and Biotechnology

Q2 Biophysics

8.

Balla, N., Kovács, F., Balázs, B., Borman, A. M., Bozó, A., Jakab, Á., Tóth, Z., Kobaissi, O., Majoros, L., Kovács, R. L.: Synergistic Interaction of Caspofungin Combined with Posaconazole against FKS Wild-Type and Mutant Candida auris Planktonic Cells and Biofilms.
Antibiotics-Basel. 11 (11), 1-12, 2022.

doi DEA WoS Scopus

Journal metrics:

Q2 Biochemistry

Q2 Infectious Diseases

Q2 Microbiology

Q2 Microbiology (medical)

Q2 Pharmacology (medical)

Q1 Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

9.

Vitális, E., Nagy, F., Tóth, Z., Forgács, L., Bozó, A., Kardos, G., Majoros, L., Kovács, R. L.: Candida biofilm production is associated with higher mortality in patients with candidaemia.
Mycoses. 63 (4), 352-360, 2020.

doi DEA

Journal metrics:

Q1 Dermatology

Q2 Infectious Diseases

Q1 Medicine (miscellaneous)

10.

Nagy, F., Tóth, Z., Bozó, A., Czeglédi, A., Rebenku, I., Majoros, L., Kovács, R. L.: Fluconazole is not inferior than caspofungin, micafungin or amphotericin B in the presence of 50% human serum against Candida albicans and Candida parapsilosis biofilms.
Med. Mycol. 57 (5), 573-581, 2019.

doi DEA WoS Scopus

Journal metrics:

Q2 Infectious Diseases

Q1 Medicine (miscellaneous)

D1 Veterinary (miscellaneous)

11.

Kovács, R. L., Nagy, F., Tóth, Z., Bozó, A., Balázs, B., Majoros, L.: Synergistic effect of nikkomycin Z with caspofungin and micafungin against Candida albicans and Candida parapsilosis biofilms.
Lett. Appl. Microbiol. 69 (4), 271-278, 2019.

doi DEA

Journal metrics:

Q2 Applied Microbiology and Biotechnology

12.

Nagy, F., Bozó, A., Tóth, Z., Daróczi, L., Majoros, L., Kovács, R. L.: In vitro antifungal susceptibility patterns of planktonic and sessile Candida kefyr clinical isolates.
Med. Mycol. 56 (4), 493-500, 2018.

doi DEA WoS Scopus

Journal metrics:

Q2 Infectious Diseases

Q1 Medicine (miscellaneous)

D1 Veterinary (miscellaneous)

13.

Kardos, T., Kovács, R. L., Kardos, G., Varga, I., Bozó, A., Tóth, Z., Nagy, F., Majoros, L.: Poor in vivo efficacy of caspofungin, micafungin and amphotericin B against wild-type Candida krusei clinical isolates does not correlate with in vitro susceptibility results.
J. Chemother. 30 (4), 233-239, 2018.

doi DEA

Journal metrics:

Q3 Infectious Diseases

Q2 Medicine (miscellaneous)

Q3 Oncology

Q3 Pharmacology

Q3 Pharmacology (medical)

14.

Kovács, R. L., Nagy, F., Tóth, Z., Bozó, A., Majoros, L.: The effect of human serum on the efficacy of traditional antifungals against Candida albicans and Candida parapsilosis biofilms.
Med. Mycol. 56, S131, 2018.

DEA

15.

Kovács, R. L., Tóth, Z., Nagy, F., Daróczi, L., Bozó, A., Majoros, L.: Activity of exogenous tyrosol in combination with caspofungin and micafungin against Candida parapsilosis sessile cells.
J. Appl. Microbiol. 122 (6), 1529-1536, 2017.

doi DEA WoS Scopus

Journal metrics:

Q2 Applied Microbiology and Biotechnology

Q2 Biotechnology

Q2 Medicine (miscellaneous)

16.

Saleh, Q., Kovács, R. L., Kardos, G., Gesztelyi, R., Kardos, T., Bozó, A., Majoros, L.: Decreased Killing Activity of Micafungin Against Candida guilliermondii, Candida lusitaniae, and Candida kefyr in the Presence of Human Serum.
Microb. Drug Resist. 23 (6), 764-770, 2017.

doi DEA

Journal metrics:

Q3 Immunology

Q1 Medicine (miscellaneous)

Q2 Microbiology

Q2 Microbiology (medical)

Q2 Pharmacology

17.

Kovács, R. L., Saleh, Q., Bozó, A., Tóth, Z., Gesztelyi, R., Kardos, T., Kardos, G., Takács, I., Majoros, L.: Killing Activity of Micafungin Against Candida albicans, C. dubliniensis and Candida africana in the Presence of Human Serum.
Mycopathologia. 182 (11-12), 979-987, 2017.

doi DEA

Journal metrics:

Q2 Agronomy and Crop Science

Q2 Applied Microbiology and Biotechnology

Q3 Microbiology

Q2 Plant Science

Q2 Veterinary (miscellaneous)

18.

Kardos, T., Saleh, Q., Kovács, R. L., Gesztelyi, R., Kardos, G., Bozó, A., Tóth, Z., Majoros, L.: Postantifungal effect of micafungin against Candida albicans, Candida dubliniensis and Candida africana in the presence and absence of serum.
New Microbiol. 40 (4), 286-288, 2017.

DEA

Journal metrics:

Q2 Medicine (miscellaneous)

Q2 Microbiology (medical)

19.

Kovács, R. L., Nagy, F., Bozó, A., Tóth, Z., Daróczi, L., Kardos, G., Majoros, L.: The in vitro susceptibility pattern of C. kefyr planktonic cells and biofilms against traditional antifungal agents.
Acta Microbiol. Immunol. Hung. 62, 152, 2017.

DEA

20.

Kovács, R. L., Bozó, A., Gesztelyi, R., Domán, M., Kardos, G., Nagy, F., Tóth, Z., Majoros, L.: Effect of caspofungin and micafungin in combination with farnesol against Candida parapsilosis biofilms.
Int. J. Antimicrob. Agents. 47 (4), 304-310, 2016.

doi DEA

Journal metrics:

Q1 Infectious Diseases

D1 Medicine (miscellaneous)

Q1 Microbiology (medical)

D1 Pharmacology (medical)

21.

Domán, M., Kovács, R. L., Kardos, G., Gesztelyi, R., Juhász, B., Bozó, A., Kardos, T., Saleh, Q., Majoros, L.: Killing rates of caspofungin in 50 percent serum correlate with caspofungin efficacy against Candida albicans in a neutropenic murine model.
Current Drug Del. 13 (2), 255-264, 2016.

doi DEA

Journal metrics:

Q2 Pharmaceutical Science

22.

Bozó, A., Domán, M., Majoros, L., Kardos, G., Varga, I., Kovács, R. L.: The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model.
J. Microbiol. 54 (11), 753-760, 2016.

doi DEA

Journal metrics:

Q2 Applied Microbiology and Biotechnology

Q2 Medicine (miscellaneous)

Q3 Microbiology

23.

Kovács, R. L., Bozó, A., Nagy, F., Tóth, Z., Majoros, L.: The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model.
Acta Microbiol. Immunol. Hung. 64, 16, 2016.

DEA

24.

Domán, M., Kovács, R. L., Perlin, D., Kardos, G., Gesztelyi, R., Juhász, B., Bozó, A., Majoros, L.: Dose escalation studies with caspofungin against Candida glabrata.
J. Med. Microbiol. 64 (9), 998-1007, 2015.

doi DEA

Journal metrics:

Q1 Medicine (miscellaneous)

Q2 Microbiology

Q2 Microbiology (medical)

25.

Kovács, R. L., Bozó, A., Domán, M., Nagy, F., Tóth, Z., Majoros, L.: Effect of caspofungin and micafungin in combination with farnesol against Candida parapsilosis biofilms.
Mycoses. 58, 79-80, 2015.

DEA

Publication list